检索结果-南通市图书馆

efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer

引用

Chinese Journal of Cancer Research 2016年第3期28卷 330-338页

作者： Huiping Li Bin Shao Yin Yan Guohong Song Xiaoran Liu Jing Wang Xu Liang Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Department of Breast OncologyPeking University Cancer Hospital & Institute

Objective： To observe the efficacy and safety of trastuzumab combined with chemotherapy in patients with human epidermal growth factor receptor 2 （HER2）-overexpressing advanced breast cancer. Methods： A total of 90 patients with HER2-overexpressing advanced breast cancer were enrolled in this study. All patients were diagnosed with ductal invasive breast cancer by pathological analysis, and were aged between 31-73 years with a median of 51 years. HER2-positivity was defined as 3（＋） staining in immunochemistry or amplification of fluorescence in situ hybridization （FISH, ratio ≥2.0）. Trastuzumab was administered in combination with chemotherapy as first-line treatment and beyond progression as a second- line, third-line, and above treatment in 90, 34, 14, and 6 patients, respectively. The chemotherapy regimen was given according to normal clinical practice. The response rate was evaluated every two cycles, and the primary endpoints were progression-free survival （PFS） and overall survival （OS）. Survival curves were estimated by using Kaplan-Meier graphs and were compared by using log-rank test statistics. Multivariate analysis was done using Cox＇s proportional hazards regression model, and the level of significance was P〈0.05. Results： All 90 patients received at least one dose of trastuzumab, and efficacy could be evaluated in 85 patients. The median follow-up was 50 months. In total, 72 （80.00%） patients had visceral metastasis, and 43 （47.78%） patients had progressed after one or more extensive chemotherapy regimens for metastatic diseases. The median PFS for first-line trastuzumab was 10 months （range, 2-59 months）, and the median OS after metastasis or initially local advanced disease was 22 months （range, 2-1 16 months）. Conclusions： Trastuzumab combined with chemotherapy was active and well-tolerated as a first-line treatment and even beyond progression in HER2-overexpressing advanced breast cancer as a second-line or third-line treatment. However, its efficac

关键词： Trastuzumab chemotherapy advanced breast cancer efficacy and safety

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

efficacy and safety of perioperative therapy for locally resectable gastric cancer:A network meta-analysis of randomized clinical trials

引用

World Journal of Gastrointestinal Oncology 2024年第3期16卷 1046-1058页

作者： Zi-Yu Kuang Qian-Hui Sun Lu-Chang Cao Xin-Yi Ma Jia-Xi Wang Ke-Xin Liu Jie Li Graduate College Beijing University of Traditional Chinese MedicineBeijing 100029China Oncology Department Guang’anmen HospitalChina Academy of Chinese Medical SciencesBeijing 100053China

BACKGROUND Gastric cancer(GC)is the fifth most commonly diagnosed malignancy worldwide,with over 1 million new cases per year,and the third leading cause of cancer-related *** To determine the optimal perioperative treatment regimen for patients with locally resectable *** A comprehensive literature search was conducted,focusing on phase II/III randomized controlled trials(RCTs)assessing perioperative chemotherapy and chemoradiotherapy in treating locally resectable *** R0 resection rate,overall survival(OS),disease-free survival(DFS),and incidence of grade 3 or higher nonsurgical severe adverse events(SAEs)associated with various perioperative regimens were analyzed.A Bayesian network meta-analysis was performed to compare treatment regimens and rank their *** Thirty RCTs involving 8346 patients were included in this *** XELOX plus neoadjuvant radiotherapy and neoadjuvant CF were found to significantly improve the R0 resection rate compared with surgery alone,and the former had the highest probability of being the most effective option in this *** plus adjuvant FLOT was associated with the highest probability of being the best regimen for improving *** to limited data,no definitive ranking could be determined for *** nonsurgical SAEs,FLO has emerged as the safest treatment *** This study provides valuable insights for clinicians when selecting perioperative treatment regimens for patients with locally resectable *** studies are required to validate these findings.

关键词： Gastric cancer Perioperative treatment Network meta-analysis efficacy and safety

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Computerized tomography-guided therapeutic percutaneous puncture catheter drainage-combined with somatostatin for severe acute pancreatitis: An analysis of efficacy and safety

引用

World Journal of Gastrointestinal Surgery 2024年第1期16卷 59-66页

作者： Xue-Lan Zheng Wan-Ling Li Yan-Ping Lin Ting-Long Huang Department of Critical Care Medicine The Second Affiliated Hospital of Fujian Medical UniversityQuanzhou 362000Fujian ProvinceChina CT Room The Second Affiliated Hospital of Fujian Medical UniversityQuanzhou 362000Fujian ProvinceChina

BACKGROUND Severe acute pancreatitis(SAP),a condition with rapid onset,critical condition and unsatisfactory prognosis,poses a certain threat to human health,warranting optimization of relevant treatment plans to improve treatment *** To evaluate the efficacy and safety of computerized tomography-guided the-rapeutic percutaneous puncture catheter drainage(CT-TPPCD)combined with somatostatin(SS)in the treatment of *** Forty-two SAP patients admitted to The Second Affiliated Hospital of Fujian Medical University from June 2020 to June 2023 were *** the basis of routine treatment,20 patients received SS therapy(control group)and 22 patients were given CT-TPPCD plus SS intervention(research group).The efficacy,safety(pancreatic fistula,intra-abdominal hemorrhage,sepsis,and organ dysfunction syndrome),abdominal bloating and pain relief time,bowel recovery time,hospital stay,inflammatory indicators(C-reactive protein,interleukin-6,and pro-calcitonin),and Acute Physiology and Chronic Health Evaluation(APACHE)II score of both groups were evaluated for *** Compared with the control group,the research group had a markedly higher total effective rate,faster abdominal bloating and pain relief and bowel recovery,INTRODUCTION Pancreatitis,an inflammatory disease occurring in the pancreatic tissue,is classified as either acute or chronic and is associated with high morbidity and mortality,imposing a socioeconomic burden[1,2].The pathogenesis of this disease involves early protease activation,activation of nuclear factor kappa-B-related inflammatory reactions,and infiltration of immune cells[3].Severe acute pancreatitis(SAP)is a serious condition involving systemic injury and subsequent possible organ failure,accounting for 20%of all acute pancreatitis cases[4].SAP is also characterized by rapid onset,critical illness and unsatisfactory prognosis and is correlated with serious adverse events such as systemic inflammatory response syn-drome an

关键词： Computerized tomography guidance Therapeutic percutaneous puncture catheter drainage Somatostatin Severe acute pancreatitis efficacy and safety

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase Ⅱ clinical trial

引用

World Journal of Gastroenterology 2023年第24期29卷 3871-3882页

作者： Yi-Xing Chen Ping Yang Shi-Suo Du Yuan Zhuang Cheng Huang Yong Hu Wen-Chao Zhu Yi-Yi Yu Tian-Shu Liu Zhao-Chong Zeng Department of Radiation Oncology Zhongshan HospitalFudan UniversityShanghai 200032China Liver Cancer Institute Zhongshan HospitalFudan UniversityShanghai 200032China Department of Medical Oncology Zhongshan HospitalFudan UniversityShanghai 200032China

BACKGROUND Stereotactic body radiotherapy(SBRT)and programmed cell death 1 inhibitors have shown potential in treating hepatocellular carcinoma(HCC)in retrospective *** To evaluate the efficacy of combining SBRT with sintilimab for patients with recurrent or oligometastatic *** This trial involved patients with recurrent or oligometastatic HCC intravenously treated with SBRT plus sintilimab every 3 wk for 12 mo or until disease *** primary endpoint was progression-free survival(PFS).RESULTS Twenty-five patients were enrolled from August 14,2019,to August 23,*** median treatment duration was 10.2(range,0.7-14.6)*** was delivered at a median dose of 54(range,48-60)Gy in 6(range,6-10)*** median follow-up time was 21.9(range,10.3-39.7)mo,and 32 targeted lesions among 25 patients were evaluated for treatment response according to the Response Evaluation Criteria in Solid Tumors version *** median PFS was 19.7 mo[95%confidence interval(CI):16.9-NA],with PFS rates of 68%(95%CI:52-89)and 45.3%(95%CI:28-73.4)at 12 and 24 mo,*** median overall survival(OS)was not reached,with OS rates of 91.5%(95%CI:80.8-100.0)and 83.2%(95%CI:66.5-100.0)at 12 and 24 mo,*** 1-and 2-year local control rate were 100%and 90.9%(95%CI:75.4%-100.0%),*** confirmed objective response rate and disease control rate was 96%,and 96%,*** adverse events were graded as 1 or 2,and grade 3 adverse events were observed in three *** SBRT plus sintilimab is an effective,well-tolerated treatment regimen for patients with recurrent or oligometastatic HCC.

关键词： Stereotactic body radiotherapy Programmed cell death 1 Sintilimab Hepatocellular carcinoma efficacy and safety

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease

引用

Chinese Medical Journal 2018年第16期131卷 1894-1897页

作者： Han-Rong Feng Chao Zhang Song-Min Ying Department of Pharmacology & Department of Respiratory and Critical Care Medicine Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang 310058 China

INTRODUCTION Chronic obstructive pulmonary disease （COPD） is a worldwide respiratory disease which always co-exists with multiple extrapulmonary comorbidities such as cardiovascular diseases and osteoporosis. The World Health Organization pointed out that till 2030, COPD would be the third leading reason of mortality. In spite of the advanced medical research and health-care efforts, COPD still shows continuously increasing quantity of death. Tobacco smoking, indoor and outdoor air pollution （for example, biomass thel）, virus, and pulmonary dysplasia are the main risk factors for COPD. All these factors eventually destroy lung parenchymal tissue and disturb repair and defense system, which eventually lead to emphysema and small airway fibrosis [Figure 1].

关键词： Biologic Therapies Chronic Obstructive Pulmonary Disease efficacy and safety

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Clinical evidence of neoadjuvant immunotherapy for resectable locally advanced esophageal carcinoma:A systematic review

引用

Cancer Advances 2023年第13期6卷 1-17页

作者： Zi-Hong Wu Chong Xiao Xue-Ke Li Feng-Ming You Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610072China

Background:Immune checkpoint inhibitors(ICIs)as the neoadjuvant therapy for resectable locally advanced esophageal carcinoma(rlaEC)remains challenging given the poor reports of efficacy and *** study aimed to summarize reliable evidence for the preoperative neoadjuvant immunotherapy of rlaEc by analyzing all the published clinical trials on the ICIs as the neoadjuvant therapy for ***:PubMed,Cochrane Library,Embase and *** were searched from inception until June 1st,2023,for available reports to perform a *** primary endpoints were RO resection,objective response rate(ORR),pathological complete response(pCR)and major pathological response(MPR),as well as treatment-related adverse events(AEs)and postoperative *** Stata 14.0 software was employed to estimate pooled effect ***:A total of 18 single-arm clinical trials involving 625 patients met the inclusion ***-analysis showed that,among these patients with rlaEC,the pooled R0 resection rate was 97.0%(95%CI:94.0%-99.0%),the p0oled ORR was 70.0%(95%CI:64.0%-76.0%),the p0oled pCR and MPR rate were 34.0%(95%CI:29.0%-39.0%)and 56.0%(95%CI:47.0%-65.0%)*** incidence of main treatment-related AEs and postoperative complications was about 6%-45% and 8%-19% ***:Patients with rlaEC were tolerated to neoadjuvant immunotherapy and it might be beneficial to improve *** this meta-analysis had limitations and the conclusions still needed to be validated by more rigorous phase II randomized controlled clinical trials.

关键词： immune checkpoint inhibitors resectable locally advanced esophageal carcinoma neoadjuvant therapy efficacy and safety current status

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

引用

World Journal of Clinical Cases 2024年第18期12卷 3360-3367页

作者： Hui Ying Ren-Jun Huang Xiao-Min Jing Yan Li Qun-Qiu Tong Department of General Surgery Yongkang First People's HospitalYongkang 321300Zhejiang ProvinceChina Department of Oncology Yongkang First People's HospitalYongkang 321300Zhejiang ProvinceChina

BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse *** a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC *** To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were *** these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received *** efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were *** A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two *** exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the ***-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the ***,a significantly improved QOL was evident in the *** The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving *** facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.

关键词： Cetuximab FOLFOX4 regimen Evidence-based care Advanced gastric carcinoma efficacy and safety

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：